These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 19135496

  • 1. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML.
    Vaccine; 2009 Feb 18; 27(8):1184-91. PubMed ID: 19135496
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers.
    Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, Johnson J, Liddy H, Cosgrove CA, Allavena P, Mantovani A, Béchet S, Fontaine-Thompson A, Griffin GE, Dupont F, Sansonetti PJ, Lewis DJ.
    Vaccine; 2008 Feb 13; 26(7):978-87. PubMed ID: 18207287
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.
    McKenzie R, Venkatesan MM, Wolf MK, Islam D, Grahek S, Jones AM, Bloom A, Taylor DN, Hale TL, Bourgeois AL.
    Vaccine; 2008 Jun 19; 26(26):3291-6. PubMed ID: 18468742
    [Abstract] [Full Text] [Related]

  • 4. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.
    Orr N, Katz DE, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, Cohen D, Wolf MK, Venkatesan MM, Hale TL.
    Infect Immun; 2005 Dec 19; 73(12):8027-32. PubMed ID: 16299296
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.
    Vaccine; 2006 May 01; 24(18):3735-45. PubMed ID: 16095766
    [Abstract] [Full Text] [Related]

  • 6. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.
    Kotloff KL, Pasetti MF, Barry EM, Nataro JP, Wasserman SS, Sztein MB, Picking WD, Levine MM.
    J Infect Dis; 2004 Nov 15; 190(10):1745-54. PubMed ID: 15499528
    [Abstract] [Full Text] [Related]

  • 7. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.
    Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, Venkatesan M, Hale TL, Isenbarger DW, Sansonetti PJ, Black RE, Baqui AH.
    Vaccine; 2011 Feb 01; 29(6):1347-54. PubMed ID: 21040694
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.
    Bull Pan Am Health Organ; 1995 Dec 01; 29(4):312-21. PubMed ID: 8605522
    [Abstract] [Full Text] [Related]

  • 9. Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.
    Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, Deary A, Casula G, Daley A, Kelly P, Randall R, Darsley MJ.
    Infect Immun; 2006 Feb 01; 74(2):1062-71. PubMed ID: 16428753
    [Abstract] [Full Text] [Related]

  • 10. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.
    Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, Larsson CJ, Martinez T, Feller A, Ventrone CH, Sack DA, DeNearing B, Fingar A, Pierce K, Dill EA, Schwartz HI, Beardsworth EE, Kilonzo B, May JP, Lam W, Upton A, Budhram R, Kirkpatrick BD.
    Vaccine; 2010 Apr 30; 28(20):3602-8. PubMed ID: 20188175
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
    Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.
    Vaccine; 2011 Sep 16; 29(40):7009-19. PubMed ID: 21787825
    [Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults.
    Valera R, García HM, Jidy MD, Mirabal M, Armesto MI, Fando R, García L, Fernández R, Año G, Cedré B, Ramírez M, Bravo L, Serrano T, Palma S, González D, Miralles F, Medina V, Nuñez F, Plasencia Y, Martínez JC, Mandarioti A, Lugones J, Rodríguez BL, Moreno A, González D, Baro M, Solis RL, Sierra G, Barbera R, Domínguez F, Gutiérrez C, Kouri G, Campa C, Menéndez J.
    Vaccine; 2009 Nov 05; 27(47):6564-9. PubMed ID: 19720365
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
    Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN.
    Vaccine; 2006 Jan 12; 24(2):116-23. PubMed ID: 16140433
    [Abstract] [Full Text] [Related]

  • 14. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.
    McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA.
    Infect Immun; 2006 Feb 12; 74(2):994-1000. PubMed ID: 16428745
    [Abstract] [Full Text] [Related]

  • 15. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
    Mahalanabis D, Ramamurthy T, Nair GB, Ghosh A, Shaikh S, Sen B, Thungapathra M, Ghosh RK, Pazhani GP, Nandy RK, Jana S, Bhattacharya SK.
    Vaccine; 2009 Jul 30; 27(35):4850-6. PubMed ID: 19523608
    [Abstract] [Full Text] [Related]

  • 16. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.
    Steele AD, Reynders J, Scholtz F, Bos P, de Beer MC, Tumbo J, Van der Merwe CF, Delem A, De Vos B.
    J Infect Dis; 2010 Sep 01; 202 Suppl():S93-100. PubMed ID: 20684724
    [Abstract] [Full Text] [Related]

  • 17. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
    Lagos R, Avendaño A, Horwitz I, Prado V, Ferreccio C, Sotomayor V, Losonsky G, Wasserman SS, Cryz S, Kaper JB.
    Rev Med Chil; 1993 Aug 01; 121(8):857-63. PubMed ID: 8296092
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers.
    Tribble D, Kaminski R, Cantrell J, Nelson M, Porter C, Baqar S, Williams C, Arora R, Saunders J, Ananthakrishnan M, Sanders J, Zaucha G, Turbyfill R, Oaks E.
    Vaccine; 2010 Aug 23; 28(37):6076-85. PubMed ID: 20619378
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL.
    J Infect Dis; 2005 Sep 01; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [Abstract] [Full Text] [Related]

  • 20. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups.
    Qadri F, Ahmed T, Ahmed F, Begum YA, Sack DA, Svennerholm AM, PTE Study Group.
    Vaccine; 2006 Mar 06; 24(10):1726-33. PubMed ID: 16257098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.